Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04497142 · ClinicalTrials.gov registry record · Phase 1

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

A Phase 1 study of Surgery and Seizures, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT04497142 is a Phase 1 study of Surgery and Seizures that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 12 participants, below the 52,852-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04497142, a Phase 1 study of Surgery and Seizures, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to learn more about seizures in people with primary brain tumors. It will evaluate whether an antiseizure medication decreases hyperexcitability activity around tumors and prevents seizures. The procedure and study drug involved in this study are: * Electrocorticography * Perampanel (Fycompa)

Interventions

  • DRUG Standard of Care
  • DRUG Perampanel

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2020-11-05
Est. Completion 2023-05-16
Phase Phase 1

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT04497142

The ClinicalTrials.gov registry entry for NCT04497142 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 52,852-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Surgery appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.

NCT04497142 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04497142 about?

NCT04497142 is a clinical study titled "Effect of Perampanel on Peritumoral Hyperexcitability in HGG". The purpose of this research study is to learn more about seizures in people with primary brain tumors. It will evaluate whether an antiseizure medication decreases hyperexcitability activity around tumors and prevents seizures. The procedure and study drug involved in this study are: * Electrocor...

What is the current status of trial NCT04497142?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-11-05. Estimated completion is 2023-05-16.

What conditions does trial NCT04497142 study?

This clinical trial studies the following conditions: Surgery, Seizures, Glioma, Malignant.

What interventions are being tested in trial NCT04497142?

The interventions under investigation include: Standard of Care (DRUG), Perampanel (DRUG).

Who is sponsoring clinical trial NCT04497142?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04497142 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Surgery

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.